Alma Trnačević

Prof. Alma Trnačević

Clinic of Infectious diseases, University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina, Federation of, Bosnia and Herzegovina
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2021 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
Alma TrnačevićAlma Trnačević
Alma Trnačević
AMAmer Mujkanovic
Amer Mujkanovic
NANoura Al-Salloum
Noura Al-Salloum
ASAmra Sakusic
Amra Sakusic
ETEmir Trnacevic
Emir Trnacevic
RSRichard Stratton
Richard Stratton
Background: Since the outbreak of COVID-19 pandemic, clinical data from various parts of the world have been reported. Up till now, there has been no clinical data with regards to COVID-19 from Bosnia and Herzegovina (B&H). The aim was to report on the first cohort of patients from B&H and to analyze factors that influence COVID-19 patient’s length of hospitalization (LOH).Methods: This retrospective cohort study was conducted at Tuzla University Clinical Center (UKC), B&H. It involved 25 COVID-19 positive patients that needed hospitalisation between March 28th and April 27th 2020. The LOH was measured from the time of admission to discharge. Factors analyzed induced age, BMI, presence of known comorbidities, serum creatinine and O2saturation upon admission.Results: The mean age was 52.92 ± 19.15 years and BMI 28.80 ± 4.22.LOH for patients with BMI < 25 was 9 ± SE2.646 days (CI 95% 3.814–14.816) vs 14.182 ± SE .937 (CI 95% 12.346–16.018p < 0.05; HR 5.148 CI95% 1.217 to 21.772p = 0.026) for ≥25 BMI. The mean LOH of patients with normal levels of O2 ≥ 95% was 11.667 ± SE1.202 (CI95% 8.261 to 13.739;p = 0.046), while LOH for patients with < 95% was 14.625 ± SE 1.231 CI95% 12.184 to 16.757p = 0.042; HR 3.732 CI95%1.137–12.251p = 0.03). Patients without known comorbidities had a mean LOH of 11.700 ± SE1.075 (CI 95% 9.592–13.808), while those with comorbidities had a mean of 14.8 ± 1.303 (CI 95% 12.247–17.353;p = 0.029) with HR2.552.Conclusion: LOH varied among COVID-19 patients and was prolonged when analyzed for BMI ≥25, comorbidities, elevated creatinine, and O2 saturation < 95%. Furthermore, risk factors for COVID-19 patients in B&H do not deviate from those reported in other countries.

1 January 2025 in Medical Archives
Verified
Journal Article
Open access
PDF file
DBDanijel Bijedic Bijedic
Danijel Bijedic Bijedic
EBElvir Becirovic
Elvir Becirovic
JPJasminka Petrovic
Jasminka Petrovic
HJHumera Porobic Jahic
Humera Porobic Jahic
Alma TrnačevićAlma Trnačević
Alma Trnačević
AZAzra Zigic
Azra Zigic
Background: Depressive disorder is characterized by a persistent low mood (sadness, irritability, or emptiness) or a loss of pleasure, accompanied by other cognitive, behavioral, or neurovegetative symptoms that significantly impair a person's ability to function. Anxiety and fear-related disorders are marked by excessive anxiety and fear, which lead to behavioral disturbances and cause significant distress or impair personal, family, social, educational, occupational, or other key areas of functioning. Objective: The aim of this study was to analyze whether there are differences in the development of depressive symptoms between COVID-19 patients and patients with symptoms of the flu or common cold. Methods: This is a prospective study that included sixty participants: thirty with COVID-19 and thirty without COVID-19. Data were collected from the ambulatory observational records of participants, documenting their symptoms. We analyzed the relationship between variables such as age, sex, education, and the level of potential depression. The participants were divided into two groups: one consisting of individuals with COVID-19 and the other of individuals without COVID-19. All participants were male and female, aged between 40 and 65 years, and had no previous history of depressive disorder. The first group consisted of patients with COVID-19 who were treated at home but were examined at our outpatient clinic and subsequently sent home. Results: Statistical data processing was performed using the Excel program and the R statistical data processing program. Percentages are calculated in relation to 30 respondents in each group.There was no statistically significant correlation between the level of education in Group 1 and the development of depression(Spearman ro=0.007, P=0.972). In Group 1 (Covid ) there is a statistically significant correlation between the age of the subjects and the development of depression (Spearman ro=0.44, P=0.015). A positive value of the Spearman correlation coefficient means that the score increases with the age of the respondent. Three questions with the highest score in group 1 were: Question 2=71, Questions 15 and 16=66, Question 14=65; three questions with the highest score in group 2 were: Question 2=74, Question 1 =50, Question 18=46. Conclusion: COVID-19 can contribute to the development of depression. In our study, 16.7% of patients with COVID-19 showed signs of depression, with 10% experiencing mild depression and 6.7% experiencing moderate depression. Patients in the first group, particularly those of older age, were more likely to develop mild or moderate depression associated with COVID-19. Additionally, no statistically significant correlation was found between the level of education in Group 1 and the development of depression.

21 November 2025 in COVID
Verified
Journal Article
Open access
PDF file
RJRahima Jahić
Rahima Jahić
MDMustafa Asım Demirkol
Mustafa Asım Demirkol
SUSefika Umihanic
Sefika Umihanic
JSJasmina Smajic
Jasmina Smajic
SUSekib Umihanic
Sekib Umihanic
OYOnur Yolay
Onur Yolay
During the early months of the COVID-19 pandemic, treatment protocols varied substantially among countries and even between hospitals. This study compared the clinical characteristics, management strategies, and outcomes of hospitalized COVID-19 patients treated in tertiary centers in Türkiye and Bosnia and Herzegovina. We retrospectively analyzed 1338 adults hospitalized with laboratory-confirmed SARS-CoV-2 infection: 657 patients in Tuzla (Bosnia and Herzegovina, June–December 2020) and 681 in İstanbul (Turkiye, April–May 2020). Demographic, clinical, and laboratory data, treatment details (including favipiravir use), need for invasive or non-invasive mechanical ventilation, and in-hospital mortality were extracted from medical records. Patients in Bosnia and Herzegovina were older (61.6 ± 14.4 vs. 56.9 ± 15.8 years; p < 0.001) and had longer hospital stays (9.0 ± 5.5 vs. 7.7 ± 6.1 days; p < 0.001). In the Bosnian cohort, leukocyte, neutrophil, platelet, ferritin, CRP, troponin, creatinine, AST, and ALT levels were significantly higher, whereas hemoglobin and D-dimer levels were lower. The need for ventilatory support was greater in Bosnia and Herzegovina (15.1% vs. 12.2%, p < 0.001), and overall mortality was higher (25.7% vs. 9.3%, p < 0.001). No mortality difference was observed between patients treated and not treated with favipiravir. Despite similar inclusion criteria, patients in Bosnia and Herzegovina exhibited more severe disease, greater organ involvement, and higher mortality than those in Turkiye. Favipiravir use did not influence survival. Inter-country comparisons highlight how differing patient profiles and treatment protocols may impact COVID-19 outcomes; however, interpretation should consider that the two centers contributed data from different phases of the 2020 pandemic, and that country-level differences in circulating variants, healthcare capacity, hospital strain, and evolving clinical guidelines may also have influenced the observed patterns.

Verified
Journal Article
Open access
PDF file
Alma TrnačevićAlma Trnačević
Alma Trnačević
ETEmir Trnacevic
Emir Trnacevic
MMMerjema Mahmutovic
Merjema Mahmutovic
ASAmra Serak
Amra Serak
HPHumera Porobic-Jahic
Humera Porobic-Jahic
ABAmela Becirovic
Amela Becirovic
Background: The diagnosis of urinary tract infection (UTI) remains a clinical challenge, with urine culture as the gold standard. In developing countries like Bosnia and Herzegovina, a high prevalence of antimicrobial resistance and frequent empirical treatment pose significant clinical challenges. Automated urine flow cytometry has emerged as a rapid tool to optimize diagnostic processes. Objectives: To determine the correlation of age, gender, and laboratory parameters—such as white blood cell (WBC) count, neutrophil count, and C-reactive protein (CRP)—with both urinary bacterial counts and urine culture results. Methods: This retrospective study analyzed 200 adult patients (≥18 years) with symptoms suggestive of UTI at the University Clinical Center Tuzla. Data on age, gender, WBC, neutrophils, CRP, and urine flow cytometry (Sysmex UF-4000) were collected. Statistical analysis was performed using R software (version 4.5.1), utilizing logistic regression models via the ‘glm’ function to identify independent predictors, with statistical significance set at p < 0.05. Results: The mean age of the population was 68.61 ± 15.19 years. Logistic regression demonstrated that WBC count (OR = 1.06, p = 0.004), neutrophil count (OR = 1.04, p = 0.014), and patient age (OR = 1.03, p = 0.001) were significant independent predictors of UTI. Furthermore, patients with a urinary bacterial count > 1200/μL had 83 times higher odds of a positive urine culture (OR = 83, 95% CI 32.25–200, p < 0.001). Conversely, CRP levels and gender were not significant predictors (p > 0.05). Conclusions: Patient age, WBC, and neutrophil counts are key factors for predicting UTIs. Integrating these parameters with urine flow cytometry bacterial counts can significantly enhance diagnostic accuracy and rapid screening in clinical practice.

28 May 2025
Verified
Book Chapter
Open access
JPJasminka Petrović
Jasminka Petrović
DBDanijel Bijedić
Danijel Bijedić
Alma TrnačevićAlma Trnačević
Alma Trnačević
AHAzra Gutić Hodžić
Azra Gutić Hodžić
HPHumera Porobić-Jahić
Humera Porobić-Jahić
DPDilista Piljić
Dilista Piljić
The fact that >257 million people suffer from chronic hepatitis B in the world aroused interest in presenting the case of an icteric patient with the symptoms of acute viral hepatitis and with the markers of hepatitis that initially left us in doubt. A 47-year-old woman suffering from malaise and fatigue, severe abdominal pain, icterus and vomiting was referred to a gastroenterologist, and due to suspicion of choledocholithiasis and verified cholelithiasis by a surgeon, the patient was admitted to the Clinic for Surgery. After ruling out the obstruction of the bile ducts, an infectious disease specialist was consulted, and the patient with HBsAg negative and anti HBcIgM antibody positive was transferred to the Clinic for Infectious Diseases. A molecular PCR DNA HBV was performed and viremia was confirmed; parenteral antibiotic therapy was continued. Considering the deterioration of biochemical liver tests and changes in the patient’s mental status, antiviral therapy was introduced. Liver tests were gradually restored, the patient’s clinical condition significantly improved, and after 48 days of hospital treatment, the patient was discharged. In this case, we remembered that HBsAg is an important marker in the detection of hepatitis B virus in patients, but it is not a decisive marker in acute hepatitis B, especially in the case of a more severe form of the disease.